Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR., Ewer KJ., Berrie E., Bibi S., Bittaye M., Carroll MW., Flaxman A., Fuskova M., Gorringe A., Hallis B., Kerridge S., Makinson R., Mellors J., Minassian A., Moore M., Mujadidi Y., Rollier CS., Song R., Snape MD., Tarrant R., Watson MEE., Wright D., Douglas AD., Gilbert S., Pollard AJ.
A Correction to this paper has been published: https://doi.org/10.1038/s41591-021-01372-z.